Markus Pfirrmann

Topics of particular interest

• Methods, design and analysis of clinical trials
• Prognostic modelling
• Survival analysis
• Analysis of competing risks

Currently ongoing studies and projects

• CML V TIGER study: A prospective, randomized, open-labelled, multicentre clinical trial on the Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.
• DasaHIT study: A prospective, randomized, open-labelled, dose-finding study to investigate the tolerability and efficacy to give a medication 5 out of 7 days vs. giving the medication daily.
• ENDURE study: A prospective, randomized, open-labelled for investigating the efficacy and safety of pegylated proline interferon alpha 2b (AOP2014) in maintaining deep molecular remissions in patients with CML who discontinue ABL-kinase inhibitor therapy - a randomized phase II, multicentre trial with post-study follow-up.
• FASCINATION study: A prospective, non-randomized, open-labelled multicentre trial with respect to the achievement of deep molecular response with the combination of ATP competing BCR-ABL1 inhibitors with asciminib in newly diagnosed CML patients.
• TRACE study: A prospective, randomized, double-blind, placebo controlled multicentre trial regarding multivirus-specific T cell transfer against CMV, EBV, and AdV infections after allogeneic stem cell transplantation.
• Fr1Da study: A Prospective, randomized study to investigate the oral administration of insulin as a secondary prevention for patients with type 1 diabetes.
• NAUT study: A multicentre, prospective, interventional open label registry after first unsuccessful treatment discontinuation in CML patients estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping tyrosine kinase inhibitor (TKI) a 2nd time.
• PONTrack study: A multicentre, prospective, interventional, open label, uncontrolled registry for the assessment of CML patient status after achievement of deep molecular response with 2 years ponatinib treatment.
• Treatment-free remission registry for CML patients: A German prospective registry for the documentation of the molecular remission status of CML patients after discontinuation of treatment aiming at identification of prognostic factors for maintenance of molecular remission.
• EURO-SKI study: A European prospective registry for the documentation of the molecular remission status of CML patients after discontinuation of (mainly) imatinib treatment aiming at identification of prognostic factors for maintenance of molecular remission.

Other relevant work and membership in research groups

• Mentoring master's thesis and dissertations
• Collaboration with and support of clinical colleagues in projects requiring advanced statistical methods
• Methodical reviewer of the following journals: „Leukemia”, „Journal of Clinical Oncology”, „Lancet Oncology”, „Blood”, „BMC Medical Research Methodology”
• Member of the Committee of experts of the “Deutsche Krebshilfe”
• Member of the European Investigators on Chronic Myeloid Leukemia
• Member of the European Leukemia Net (ELN)
• Member of the competence network „Acute and chronic leukemia“